Praxis Medica
Sign in
Issue image

More articles from Volume 37, Issue 2, 2009

FUNCTIONAL ASYMMETRY OF BRAIN AND POTENTIALS P300

INFLUENCE OF DOXORUBICIN ON ELECTRICAL ACTIVITY OF THE MYOCARDIUM AND LEFT VENTRICULAR FUNCTION DURING TREATMENT OF CHILDHOOD ACUTE LYMPHOBLASTIC LEUKEMIA

MORPHOMETRIC AND STEREOLOGICAL ANALYSIS GANGLION STRUCTURES OF MYENTERIC NERVE PLEXUS, TERMINALLY PART OF HUMAN LARGE INTESTINE

MASSIVENESS OF A SICKNESS, A PATHOGENIC OF CONTAGIUM AND HENLE-KOCH POSTULATES

SOME ASPECTS OF FAMILY PLANNING - FROM MISCARRIAGE TO HEALTH EDUCATION

COMPARE AND EXAMINE FIBRINOGEN LEVEL IN PATIENTS WITH DIABETES MELLITUS TYPE 2

M. Suljić ,
M. Suljić

General hospital, Novi Pazar Serbia

View authors publications

Search this author on:

PubMed | Google Scholar
A. Jovanović
A. Jovanović

Medical faculty Priština , Kosovska Mitrovica , Kosovo*

View authors publications

Search this author on:

PubMed | Google Scholar

Published: 01.12.2009.

Volume 37, Issue 2 (2009)

pp. 37-42;

https://doi.org/10.70949/pramed200902292S

Abstract

The middle of last century it was established that the increased value registered fibrinogen in patients with coronary disease, hypertension, peripheral artery disease, patients with diabetes mellitus. Fibrinogen also participate in the earliest stages of atherosclerosis.Task of our research was to compare the level of fibrinogen in patients of type 2 diabetes mellitus without complications, and manifested in patients with apparent chronic complications as well as the correlation of fibrinogen with the parameters of metabolic control. Included 64 respondents, a close age divided into 4 groups: control group, people of type 2 diabetes mellitus without complications, people with microvascular complications, and people with macrovascular complications.The highest average value of fibrinogen in the blood we had in the group with diabetes mellitus without complications (3.47±0.26 g/l) and the lowest mean value in the control group (2.87±0.15 g/l). It is a test of correlation showed a strong correlation with the value of fibrinogen level of development of chronic complications.

Keywords

fibrinogen,

diabetes mellitus,

complications

References

1.
Miller LL, Griffin EE. Regulation of net biosynthesis of albumin, fibrinogen, alpha-1 acid glycoprotein, acute phase globulin and haptoglobin by direct action of hormones on the isolated perfused liver. In: Biochemical Actions of Hormones. p. 159–86.
2.
Saito I, Aaron R, Folsom AR, Brancati FL, Duncan BB, Chambless LE, et al. Nontraditional risk factors for coronary heart disease incidence among persons with diabetes.
3.
Missov RM, Stolk RP, Bom JG. Plasma fibrinogen in NIDDM. The Rotterdam Study Diabetes Care. 19:157–9.
4.
Sowers C, J.A. Hypertension in diabetes, National High Blood Pressure Education Program. NIH Publication. (94–3530).
5.
McDonald L, Edgill M. Coagulability of the blood in ischemic heart disease. Lancet. 2:457.
6.
Festa A, R D ’Agostino, Mykkänen L, Tracy RP, Zaccaro DJ, Hales CN, et al. Relative contribution of insulin and its precursors to fibrinogen and PAI-1 in a large population with different states of glucose tolerance. In: The Insulin Resistance Atherosclerosis Study (IRAS) Arterioscler Thromb Vasc Biol. p. 562–8.
7.
Feo P, M GG, MW H. Differential effects of insulin deficiency on albumin and fibrinogen synthesis in humans. J Clin Invest. 88:833–40.
8.
Ritchie DG, Levy BA, Adams MA, Fuller GM. Regulation of fibrinogen synthesis by plasmin-derived fragments of fibrinogen and fibrin: an indirect feedback pathway. Proc Natl Acad Sci USA. 79:1530–4.
9.
Ceriello A, Giacomello R, Stel G. Hyperglycemia-induced thrombin formation in diabetes. The possible role of oxidative stress. Diabetes. 44:924–8.
10.
Bruno G. Association of fibrinogen with glycemic control and albumin excretion rate in patients with non-insulin-dependent diabetes mellitus. Atherosclerosis. 125(8):653–7.
11.
ratio in diabetes and other catabolic illnesses. Diabetes. 20:834–8.
12.
Unger RH. Glucagon and insulin.
13.
Barazzoni R, Zanetti M, Davanzo G, Kiwanuka E. Increased fibrinogen production in type 2 diabetic patients without detectable vascular complications: correlation with plasma glucagon concentrations. J Clin Endocrinol Metab. 85(9):3121–5.
14.
Thompson SG, Kienast J, Pyke SD, Haverkate F, Loo JC. Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group N Engl J Med. 332:635–41.
15.
Heinrich J, Balleisen L, Schulte H, Assman G, Loo J. Fibrinogen and factor VII in the prediction of coronary risk. In: Results from the PROCAM study in healthy men Arterioscler Thromb. p. 54–9.
16.
Wilhemsen L, Svardsuss K, Korsan-Bengsten K. Fibrinogen as a risk factor for stroke and myocardial infarction. N Engl J Med. 311:501–5.
17.
Kannel WB, Wolf PA, Castelli WP, D’Agostino RB. Fibrinogen and risk of cardiovascular disease: the Framingham Study. JAMA. 258:1183–6.

Citation

Copyright

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

Article metrics

Google scholar: See link

The statements, opinions and data contained in the journal are solely those of the individual authors and contributors and not of the publisher and the editor(s). We stay neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Most read articles

Indexed by
DOAJ
Google Scholar
ERIHPLUS
MIAR I
Crossref